Financial Performance - Revenue for the reporting period decreased by 15.42% to RMB 421,098,177.10 compared to the same period last year[11] - Net profit attributable to shareholders of the listed company decreased by 149.99% to RMB -56,234,054.72[11] - Net cash flow from operating activities decreased by 74.01% to RMB -53,554,532.87[11] - Basic earnings per share decreased by 160.00% to RMB -0.13[11] - Total assets decreased by 5.84% to RMB 1,769,938,443.19 compared to the end of the previous year[11] - Net assets attributable to shareholders of the listed company decreased by 6.28% to RMB 743,421,718.54[11] - Weighted average return on equity decreased by 4.67 percentage points to -7.32%[11] - The company reported a total operating revenue of 421.0982 million yuan for the reporting period, a 15.42% year-on-year decrease, and a net loss attributable to the parent company of 56.2341 million yuan, a 149.99% year-on-year decrease[27] - The company's revenue for the reporting period was 421,098,177.10 yuan, a decrease of 15.42% compared to the same period last year[36] - Net profit attributable to parent company shareholders was -56,234,054.72 yuan, a decrease of 150.1% compared to the same period last year[113] - Comprehensive income totaled -59,631,507.14 yuan, down 71.8% year-over-year[113] - Basic earnings per share were -0.13 yuan, a decline of 160% from the previous year[113] - Operating cash flow was -53,554,532.87 yuan, a 74.1% decrease compared to the same period last year[117] - Sales revenue from goods and services was 410,914,483.57 yuan, down 4.5% year-over-year[117] - Management expenses were 9,304,617.83 yuan, a 54.4% decrease from the previous year[115] - Financial expenses were -67,925.18 yuan, a 106.7% decrease compared to the same period last year[115] - Credit impairment losses were -41,537,992.23 yuan, a significant increase from 400,000.00 yuan in the previous year[115] - Operating profit was -50,767,917.07 yuan, a 146.7% decrease year-over-year[115] - Diluted earnings per share were -0.12 yuan, a 140% decrease from the previous year[116] - Net cash flow from investment activities was -51.65 million yuan, a decrease of 145.32 million yuan compared to the same period last year[118] - Net cash flow from financing activities was 82.88 million yuan, a decrease of 143.19 million yuan compared to the same period last year[118] - The ending balance of cash and cash equivalents was 214.13 million yuan, a decrease of 276.57 million yuan compared to the same period last year[118] - Net cash flow from operating activities was -6.03 million yuan, an improvement from -13.88 million yuan in the same period last year[119] - Net cash flow from investment activities was 12.46 million yuan, compared to -28.91 million yuan in the same period last year[120] - Net cash flow from financing activities was -6.36 million yuan, compared to -36.96 million yuan in the same period last year[120] - The ending balance of cash and cash equivalents was 1.57 million yuan, a decrease of 2.37 million yuan compared to the same period last year[120] - The total owner's equity at the beginning of the period was 804.20 million yuan[121] - Comprehensive income for the period decreased by RMB 56,234,054.72[122] - Owner's equity increased by RMB 6,505,493.48 due to capital contributions[122] - Total owner's equity at the end of the period was RMB 751,073,608.11[123] - Capital reserve decreased by RMB 26,134,335.62[124] - Net profit attributable to parent company owners decreased by RMB 22,494,471.61[124] - Owner's equity at the end of the period was RMB 893,813,878.94[126] - Other comprehensive income decreased by RMB 199,978.49[124] - Total owner's equity at the beginning of the period was RMB 823,002,383.80[124] - Capital reserve at the end of the period was RMB 358,477,395.76[126] - Retained earnings at the end of the period were RMB 94,490,134.36[126] - Share capital increased to 445,754,078.00 yuan, with a capital reserve of 365,681,673.47 yuan[127] - Comprehensive income for the period decreased by 50,767,874.07 yuan, impacting total owner's equity[127] - Owner's equity at the end of the period was 722,036,757.17 yuan, down from 766,299,137.76 yuan at the beginning[128] - Total owner's equity increased to 836,453,636.35 yuan by the end of the period, up from 742,548,731.20 yuan at the beginning[130] - Capital reserve decreased by 21,785,686.88 yuan during the period[129] - Owner's equity was impacted by a decrease in undistributed profits by 20,579,779.97 yuan[129] - Owner's equity was bolstered by owner contributions of 114,484,685.12 yuan[129] Market and Industry Trends - The global water fittings market reached 98.442 billion RMB in 2022 and is expected to grow at a CAGR of 5% to reach 131.433 billion RMB by 2028[16] - The US water fittings market was valued at 20.1 billion USD in 2020, accounting for 27.02% of the global market share[17] - The European water fittings market was approximately 19 billion USD in 2020, representing about a quarter of the global market[17] - The Chinese water fittings market was 13 billion USD in 2020 and is projected to grow at a CAGR of 7.8% to reach 21.9 billion USD by 2027[17] - The number of elderly people aged 60 and above in China reached 297 million, accounting for 21.1% of the total population in 2023[20] - In 2022, there were 4.8247 million new cancer cases in China, with the overall cancer incidence rate on the rise[20] - Approximately 70% of cancer patients require radiotherapy at different stages of the disease, and radiotherapy can cover 95% of cancer treatments[20] - The precision radiotherapy market in China accounted for 74.0% of the total radiotherapy market in 2022, and is expected to grow to 79.7% by 2030[20] - The market size of precision tumor radiotherapy in China reached 41 billion yuan in 2022, with a CAGR of 13.28% from 2018 to 2022, and is projected to grow to 80.9 billion yuan by 2025[20] - China's cumulative installed power generation capacity reached approximately 2.92 billion kW by the end of 2023, with solar power capacity at about 610 million kW, a 55.2% year-on-year increase, and wind power capacity at 440 million kW, a 20.7% year-on-year increase[23] Business Operations and Strategy - The company's valve and pipe fitting business primarily serves the civil construction water and gas systems, with products mainly exported to European and American markets[17] - The company adopts a make-to-order production principle, with a production model that is primarily self-manufactured and supplemented by outsourcing[17] - The company is located in Yuhuan City, Zhejiang Province, one of the largest water valve production and sales bases in China[19] - The company operates specialized cancer hospitals in multiple locations, including Dazhou, Kunming, Xi'an, and Liangshan, focusing on precision radiotherapy[21] - The company's hospitals are equipped with advanced medical imaging and radiotherapy devices, such as PET-CT, 3.0T MRI, and linear accelerators[21] - The company adopts a business model of "external acquisitions + internal growth" to expand its chain of specialized cancer hospitals[21] - The company has established medical consortium agreements with top-tier hospitals to enhance collaboration in technology, talent, and patient referrals[21] - The company plans to introduce more advanced precision radiotherapy equipment to strengthen its comprehensive cancer treatment capabilities[21] - The company has acquired four specialized cancer hospitals, including Dazhou Medical Cancer Hospital, Kunming Medical Cancer Hospital, Liangshan High-tech Cancer Hospital, and Xi'an Medical Cancer Hospital, establishing a preliminary chain and scale in the field of precision radiotherapy for tumors[22] - The company's N-type TOPCon solar cells have achieved a maximum conversion efficiency of 25.66%, with applications in residential, commercial, and centralized photovoltaic modules[24] - The company's valve and pipe fittings business faces reduced profitability due to tightening U.S. tariff policies, prompting a focus on expanding the domestic market and building overseas factories and brands[27] - Kunming Medical Cancer Hospital has enhanced its market influence by integrating online and offline expert resources, shifting from passive to active patient acquisition[27] - Liangshan High-tech Cancer Hospital plans to establish a provincial expert consultation model to improve its brand influence in Xichang[27] - The company's photovoltaic business is burdened with high fixed costs, leading to efforts in risk control and product competitiveness enhancement[27] - The company's valve and pipe fittings business has a stable customer base with large multinational corporations, though the U.S. market advantage is declining due to trade friction[28] - The company's precision radiotherapy services are positioned to capitalize on the growing demand for non-public cancer hospitals amid China's aging population and rising cancer incidence[29] - The company's photovoltaic battery segment revenue increased by 93.24% to 5,342,888.58 yuan[37] - The company sold 51% equity of Pule New Energy Technology (Taixing) Co., Ltd. to Shanghai Guosheng Xusheng Energy Technology Co., Ltd. for 0 RMB, aiming to optimize industrial structure and improve resource allocation[47] - Zhejiang Anhong Plumbing Equipment Co., Ltd., a subsidiary, reported a net profit of 6,945,067.78 RMB with total assets of 169,040,798.95 RMB and revenue of 113,281,018.11 RMB[49] - Zhejiang Yonghe Intelligent Control Technology Co., Ltd., another subsidiary, achieved a net profit of 11,915,712.43 RMB with total assets of 826,931,475.48 RMB and revenue of 224,528,892.92 RMB[49] - Pule New Energy Technology (Taixing) Co., Ltd. reported a net loss of 41,537,992.23 RMB with total assets of 409,482,088.71 RMB and revenue of 5,342,888.58 RMB[49] - The company faces risks from changes in the foreign trade environment, with the U.S. market accounting for approximately 50% of its sales[51] - The company mitigates exchange rate fluctuation risks by implementing a currency linkage mechanism with customers and using hedging tools[52] - Copper rod costs account for about 60% of production costs, and the company manages raw material price risks through dynamic tracking and strategic inventory partnerships[53] - The company faces potential risks of delayed medical insurance reimbursements as its hospital business expands[54] - The company has a significant amount of goodwill from acquiring specialized cancer hospitals and aims to reduce the risk of goodwill impairment by improving hospital profitability[55] - The company plans to apply for a comprehensive credit line not exceeding 600 million yuan for the full year of 2024[57] - The company will continue to engage in forward foreign exchange settlement and sales business[57] - The company has approved a proposal to authorize the board to issue shares to specific objects through a simplified procedure[58] - The company will not distribute cash dividends, issue bonus shares, or convert capital reserve into share capital in the first half of the year[60] - The company's 2022 restricted stock incentive plan was adjusted to grant 16.016 million shares at a price of 3.98 yuan per share to 56 incentive objects[61] - The company decided to repurchase and cancel 16,800 shares of restricted stock from 2 departed incentive objects[62] - The number of restricted shares granted under the 2022 restricted stock incentive plan was adjusted from 16.016 million shares to 22.4224 million shares[63] - The grant price of the 2022 restricted stock incentive plan was adjusted from RMB 3.98 per share to RMB 2.84 per share[63] - 52,920 restricted shares were repurchased and canceled due to the departure of 3 incentive recipients[63] - 1,118.474 million restricted shares were unlocked and became tradable in the first unlocking period of the 2022 restricted stock incentive plan[63] - 184.2247 million restricted shares were repurchased and canceled due to the departure of 4 incentive recipients and unmet performance targets[63] - 711.8089 million restricted shares were unlocked and became tradable in the second unlocking period of the 2022 restricted stock incentive plan[63] - The company actively participated in nearly 40 public welfare activities in the first half of 2024, including patient care, free clinics, and health education[67] - The company strictly complied with labor laws and established a comprehensive human resource management system to protect employee rights[67] - The company has established a comprehensive quality management system for its valve and pipe fittings products, ensuring high-quality medical technology, services, and products[68] - The company has formed strategic partnerships with large domestic and international medical equipment suppliers to provide advanced tumor precision radiotherapy facilities and technologies[68] - The company reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[69] - The company's semi-annual financial report was not audited[69] - The company won a lawsuit involving a private equity fund, with no liability for damages, involving an amount of 1.4819 million yuan[70] - The company is involved in multiple ongoing lawsuits with material suppliers, with amounts ranging from 7.15 thousand yuan to 1.09596 million yuan[70] - The company confirmed 526.1 thousand yuan in employee compensation payable as of June 30, 2024, related to labor arbitration at Xi'an Medical Cancer Hospital[71] - The company confirmed 1.6324 million yuan in other current liabilities as of June 30, 2024, related to a rent dispute arbitration at Xi'an Medical Cancer Hospital[71] - The company reported no penalties or rectifications during the reporting period[72] - The company had no significant related-party transactions during the reporting period[73][74][75] - The company continues to lease office space in Shanghai with a 5-year lease agreement[80] - The company leases operating premises for Dazhou Medical Cancer Hospital with a 10-year lease agreement[80] - The company leases operating premises for Kunming Medical Cancer Hospital with a 13-year lease agreement[80] - The company leases part of Chengdu Shanshui Shang property to Chengdu Gaoshang Medical Imaging Diagnosis Center and Chengdu Gaoxin Heyue Gaoshang Physical Examination Clinic with a 13.5-year lease agreement[80] - The company leases operating premises for Liangshan Gaoxin Cancer Hospital with a 10-year lease agreement[80] - The company leases operating premises for Xi'an Medical Cancer Hospital with a 15-year lease agreement currently under arbitration[80] - The company leases production plant for Pule Taixing with a 10-year lease agreement[80] - The company leases office space in Chengdu with a 3-year lease agreement[80] - The total approved guarantee amount for subsidiaries at the end of the reporting period is 1,600 million yuan[81] - The actual guarantee balance for subsidiaries at the end of the reporting period is 1,600 million yuan[81] - Shareholder Xia Zuwang holds 23,635,966 shares, accounting for 5.30% of the company's total shares, becoming the fourth largest shareholder[87] - The company will not distribute profits for 2023, including no cash dividends, no stock dividends, and no capital reserve to share capital conversion[87] - The company and its subsidiaries have applied for a comprehensive credit line of up to RMB 600 million for 2024[87] - The company will conduct forward foreign exchange contracts with a cumulative amount not exceeding USD 100 million to mitigate exchange rate risks[88] - The company is authorized to issue shares to specific objects with a financing amount not exceeding RMB 300 million and 20% of the net assets at the end of the previous year[88] - Shareholder Ying Xueqing transferred 24,500,000 shares (5.50% of total shares) to Yan Yanjing at a price of RMB 4.45 per share[88] - The company plans to transfer 51% equity of Pule Technology to Guosheng Xusheng Energy Technology, removing Pule Technology from the consolidated financial statements[89] - The company's total shares remain unchanged at 445,754,078, with 96.70% being unrestricted shares[90] - The company's limited-sale shares remain at 14,712,740, accounting for 3.30% of total shares[90] - Key executives hold restricted shares due to senior management lock-up and equity incentive restrictions[91] - Total restricted shares for equity incentive plan amount to 14,712,740 shares[93] - The total number of ordinary shareholders at the end of the reporting period is 25,228[94] - Cao Deli holds 9.65% of the company's shares, totaling 43,004,034 shares[94] - Chen Xianyun holds 7.34% of the company's shares, totaling 32,717,104 shares[97] - Ying Xueqing holds 5.50% of the company's shares, totaling 24,500,000 shares[97] - Xia Zuwang holds 5.30% of the company's shares, totaling 23,635,966 shares[97] - Su Jinfei holds 4.52% of the company's shares, totaling 20,127,240 shares[97] - Yang Yingli holds 3.70% of the company's shares, totaling 16,492,500 shares[97] - Yu Yaqun holds 3.30% of the company's shares, totaling 14,700,000 shares[97] - Deng Lili holds 0

本表已于 2024年8月28 日获董事会批准。 法定代表人: 主管会计工作负责人 永和流体智控股份有限公司 2024年1-6 月非经营性资金占用及其他关联资金往来情况汇总表 单位:万元 | 非经营性资金占用 | 资金占用方名称 | | | | 占用方与上市公 上市公司核算的 2024 年 1 月 1 日 2024 年 1-6 月往来资\2024 年 1-6 月往来资\2024 年 1-6 月 20 住 | | | | 占用形成原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 司的关联关系 | 会计科目 | 往来资金余额 | 生金额(不含利息) | 金的利息(如有) | 计发生金额 | 来资金余额 | | | | 控股股东、实际控制人 | | | A THE REAL PRODUCTION | | | | | | | | | 及其附属企业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 前控股股东、实际控制 | | | | | | | | ...

证券代码：002795 证券简称：永和智控 公告编号：2024-031 永和流体智控股份有限公司 关于控股股东、实际控制人的一致行动人权益变动超过1% 的公告 公司控股股东、实际控制人的一致行动人余娅群保证向本公司提供的信息 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 永和流体智控股份有限公司（以下简称"公司"）于近日收到本公司控股股东、 实际控制人曹德莅的一致行动人余娅群出具的《告知函》，获悉：2024年8月16 日至2024年8月23日，余娅群在诚通证券股份有限公司（以下简称"诚通证券"） 客户信用交易担保证券账户所持有的部分公司股份被诚通证券强制平仓，被动减 持公司股份数量为5,640,000股，占公司总股本的比例为1.27%，被动减持获得资 金全部用于偿还余娅群在诚通证券的融资负债。 根据《证券法》《深圳证券交易所上市公司自律监管指引第1号——主板上 市公司规范运作》《上市公司收购管理办法》《上市公司股东减持股份管理暂行 办法》《深圳证券交易所上市公司自律监管指引第18号——股东及董事、监事、 高级管理人员减持股份》 ...

证券代码：002795 证券简称：永和智控 公告编号：2024-030 一、权益变动基本情况 （一）本次减持股份来源：二级市场增持。 （二）权益变动股份情况 永和流体智控股份有限公司 关于控股股东、实际控制人的一致行动人权益变动超过1% 的公告 公司控股股东、实际控制人的一致行动人余娅群保证向本公司提供的信息 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 永和流体智控股份有限公司（以下简称"公司"）于近日收到本公司控股股东、 实际控制人曹德莅的一致行动人余娅群出具的《告知函》，获悉：余娅群于2022 年3月18日通过集中竞价交易方式增持公司股份1,345,400股，占公司总股本比例 为0.64%。2023年3月21日至2023年3月22日通过集中竞价交易方式减持公司股份 3,098,456股，占公司总股本比例为0.97%。2024年8月13日至2024年8月15日在诚 通证券股份有限公司（以下简称"诚通证券"）客户信用交易担保证券账户（以下 简称：信用担保账户）所持有的部分公司股份被诚通证券强制平仓，被动减持公 司股份数量为1 ...

关于控股股东、实际控制人部分股份质押的公告 公司控股股东、实际控制人曹德莅保证向本公司提供的信息内容真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 证券代码：002795 证券简称：永和智控 公告编号：2024-029 永和流体智控股份有限公司 | | | | | | 本次质 | 本次质 | 已质押股份 | | 未质押股份 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 押后累 | 押后累 | 情况 | | 情况 | | | | | | 本次质押 | 本次质押 | 计质押 | 计质押 | | | | | | 股东名 | 持股数量 | 持股 | 前累计质 | 后累计质 | 股份数 | 股份数 | 已质押股 | | 未质押股 | | | 称 | （股） | 比例 | 押股份数 | 押股份数 | | | | 占已质 | | 占未质 | | | | | 量（股） | 量（股） | 量占其 | 量占公 | 份限售和 | 押股份 | 份限售和 | 押股份 | | | | | | | 所持股 | ...

证券代码：002795 证券简称：永和智控 公告编号：2024-028 永和流体智控股份有限公司 关于2022年限制性股票激励计划第二个解除限售期解除限售股 票上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、永和流体智控股份有限公司（以下简称"公司"）2022 年限制性股票激励 计划第二个解除限售期符合解除限售条件的激励对象共计 49 名，可解除限售的 限制性股票数量 7,118,089 股，占公司目前总股本的 1.5969%。 2、本次解除限售的限制性股票的上市流通日为 2024 年 7 月 15 日。 公司于 2024 年 4 月 26 日召开了第五届董事会第十次会议与第五届监事会第 九次会议，审议通过了《关于公司 2022 年限制性股票激励计划第二个解除限售 期解除限售条件部分成就的议案》。鉴于公司 2022 年度限制性股票激励计划第 二个解除限售期解除限售条件已经部分成就，根据公司 2021 年年度股东大会的 授权，公司按照规定为本次符合解除限售条件的激励对象办理第二个解除限售期 解除限售相关事宜。现将相关事项公告 ...

一、本期业绩预计情况 本次业绩预告相关数据是公司财务部门初步测算的结果，未经会计师事务所 2、公司2022年限制性股票激励计划向53名激励对象授予2,236.948万股限制 性股票，截至2024年6月30日尚未解锁的限制性股票为1,118.474万股。根据《企 业会计准则第11号—股份支付》、《企业会计准则第22号—金融工具确认和计量》 的相关规定，上述限制性股票在2024年半年度摊销成本预估约786.66万元，该成 本将在2024年半年度管理费用中列支。 永和流体智控股份有限公司 2、业绩预告情况： 预计净利润为负值 扭亏为盈 同向上升同向下 三、业绩变动原因说明 本次业绩预告数据是公司财务部门初步测算的结果，未经会计师事务所审计， 具体财务数据以公司披露的《2024 年半年度报告》为准。敬请广大投资者谨慎决 策，注意投资风险。 2024 年半年度业绩预告 | --- | --- | --- | |---------------------|-----------------------------------------|------------------------| | 降 \n项目 | 本报告期 ...

证券代码：002795 证券简称：永和智控 公告编号：2024-026 永和流体智控股份有限公司 关于控股股东、实际控制人协议转让公司部分股份完成过 户登记的公告 公司控股股东、实际控制人曹德莅保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 永和流体智控股份有限公司（以下简称"公司"或"本公司"）于近日收到公司 控股股东、实际控制人曹德莅的通知，其通过协议方式转让给夏祖望的23,635,966 股股份已办理完毕相关股份过户登记手续，并取得了中国证券登记结算有限责任 公司出具的《证券过户登记确认书》，现将相关情况公告如下： 一、股份协议转让概述 2023 年 11 月 9 日，公司控股股东、实际控制人曹德莅分别与广东普乐绿色 能源控股有限公司（以下简称"广东普乐"）、夏祖望签署了《股份转让协议》， 曹德莅拟将其持有的公司 35,660,326 股股份（占公司股份总数的 8.00%）以每股 8.9736 元的价格转让给广东普乐；拟将其持有的公司 23,635,966 股股份（占公司 ...

证券代码：002795 证券简称：永和智控 公告编号：2024-025 永和流体智控股份有限公司 关于持股5%以上股东签署《股份转让协议》暨权益变动的 提示性公告 公司持股5%以上的股东应雪青保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、永和流体智控股份有限公司（以下简称"公司"、"本公司"或"永和智控"） 持股 5%以上股东应雪青（以下简称"出让方"）于 2024 年 5 月 26 日与颜燕晶（以 下简称"受让方"，"出让方"和"受让方"合称为"双方"）签署了《股份转让协议》， 应雪青拟将其持有的永和智控 24,500,000 股无限售流通股股份（占公司股份总数 的 5.50%，以下称"标的股份"）以每股 4.45 元的价格协议转让给颜燕晶。 2、本次权益变动不涉及亦不会导致本公司控股股东、实际控制人发生变化。 3、双方承诺，本次股份转让完成后，将各自按照相应规则遵守股份减持的 相关规定。本次协议转让受让方受让标的股份的资金为自有资金。 4、本次股份转让尚需 ...

永和流体智控股份有限公司 简式权益变动报告书 上市公司名称：永和流体智控股份有限公司 信息披露义务人：颜燕晶 住所/通讯地址：浙江省玉环市清港镇**** 一致行动人：尤贤松（配偶） 住所/通讯地址：浙江省玉环市清港镇**** 一致行动人：张连琴（母亲） 住所/通讯地址：浙江省玉环市清港镇**** 一致行动人：赵雪锋（兄弟之配偶） 住所/通讯地址：浙江省玉环市清港镇**** 股份变动性质：股份增加（协议转让） 简式权益变动报告书签署日期：2024 年 5 月 26 日 股票上市地点：深圳证券交易所 股票简称：永和智控 股票代码：002795 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》《上市公司收购管理办 法》《公开发行证券的公司信息披露内容与格式准则第 15 号——权益变动报告 书》及相关法律法规编写本权益变动报告书（以下简称"本报告书"）。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》《公开发行 证券的公司信息披露内容与格式准则第 15 号——权益变动报告书》的规定，本 报告书已全面披露了信息披露义务人在永和流体智控股 ...